Mortality Benefit of Alirocumab: A Bayesian Perspective

BACKGROUND: The ODYSSEY OUTCOMES (Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome) trial demonstrated that alirocumab reduced major cardiovascular events. However, because of the hierarchical testing strategy used for the multiple outcomes examined, the observed reduction in all...

Descripción completa

Detalles Bibliográficos
Autores principales: Labos, Christopher, Brophy, James M., Sniderman, Allan, Thanassoulis, George
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818032/
https://www.ncbi.nlm.nih.gov/pubmed/31599200
http://dx.doi.org/10.1161/JAHA.119.013170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6818032/
https://www.ncbi.nlm.nih.gov/pubmed/31599200
http://dx.doi.org/10.1161/JAHA.119.013170

Ejemplares similares